The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly last week to recommend new labels on gadolinium-based contrast agents (GBCAs) warning of the possibility of gadolinium retention in the body following administration. The labels...
Contrast Media
-
-
Here are several updates in medical imaging contrast media agents.
-
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and sodium ioxaglate) and Optimark (gadoversetamide).
-
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for magnetic resonance imaging (MRI) has not identified adverse health affects from gadolinium retained in the brain. The FDA released a drug safety communication regarding all...
-
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new recommendations on procedures employing gadolinium-based contrast agents, in which the committee recommended suspension of marketing authorization for four agents.
News | Contrast Media | October 10, 2017
October 10, 2017 — Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de...
Image courtesy of Bayer
Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based...
News | Contrast Media | September 12, 2017
September 12, 2017 — The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC)...
News | Contrast Media | September 07, 2017
September 7, 2017 — The U.S. Food and Drug Administration (FDA) held a meeting of the Medical Imaging Drugs Advisory...
Technology | Magnetic Resonance Imaging (MRI) | September 06, 2017
September 6, 2017 — Guerbet LLC USA announced that the U.S. Food and Drug Administration (FDA) has approved Dotarem...
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of...
News | Contrast Media | August 15, 2017
August 15, 2017 — The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in...
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products:...
News | Contrast Media | July 17, 2017
July 17, 2017 — The American College of Radiology (ACR) recently revised its authoritative guide for the safe and...
Technology | CT Angiography (CTA) | June 16, 2017
June 16, 2017 — The U.S. Food and Drug Administration (FDA) has expanded the indication for GE Healthcare’s ...
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
May 25, 2017 — A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based...
The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017
News | Prostate Cancer | May 24, 2017
May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
Improving Efficiency and Reducing Waste
The volume of computed tomography (CT) imaging exams continues to...
News | Contrast Media | March 13, 2017
March 13, 2017 — The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently...
(a) Photograph of the sample in waterbath. (b) Empty image of full MuCLS beam. (c) Quasi-mono-energetic angiography image of a porcine heart acquired at the MuCLS, with iodine-based contrast agent injected into the left coronary artery. Visible are the left anterior descending artery (LAD) and the left circumflex artery (LCX). Image courtesy of the authors.
News | Angiography | March 10, 2017
March 10, 2017 — The most prevalent method for obtaining images of clogged coronary vessels is coronary...
Feature | Contrast Media Injectors | March 02, 2017 | By Jeff Zagoudis
With medical imaging use on the rise, contrast media...
Technology | Contrast Media | February 02, 2017
February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a...
A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians
News | Contrast Media | January 30, 2017
January 30, 2017 — Intravenous contrast media (typically iohexol or iodixanol) used in...